Butyric Acid

Butyric Acid

SCHEMBL4160052

C#CCN(C)S(=O)(=O)c1ccc2[nH]c(=O)c3[nH]ccc3c2c1.CCCC(=O)O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.45
RXFP1 Q9HBX9 3/20 0.40
GAA P10253 1/20 0.39
ALDH1A1 P00352 5/20 0.35
HPGD P15428 5/20 0.35
HSD17B10 Q99714 3/20 0.35
USP2 O75604 2/20 0.35
POLB P06746 4/20 0.34
MAPT P10636 6/20 0.34
LMNA P02545 4/20 0.34
GLA P06280 1/20 0.34
TP53 P04637 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ADRB2 P07550 1/20 0.34
RECQL P46063 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
BRAF P15056 1/20 0.33
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL4163900 0.91 KDM4E (0.45) KDM4ERXFP1GAAALDH1A1HPGD
Butyric Acid SCHEMBL4169890 0.89 KDM4E (0.59) KDM4ERXFP1GAAALDH1A1POLB
Butyric Acid SCHEMBL4162647 0.88 RXFP1 (0.42) KDM4ERXFP1GAAALDH1A1HPGD
Butyric Acid SCHEMBL4163999 0.87 KDM4E (0.47) KDM4ERXFP1GAAALDH1A1HPGD
Butyric Acid SCHEMBL4157688 0.86 KDM4E (0.51) KDM4ERXFP1GAAALDH1A1POLB
Butyric Acid SCHEMBL4166410 0.85 KDM4E (0.49) KDM4ERXFP1GAAALDH1A1HPGD
Butyric Acid SCHEMBL4156383 0.85 KDM4E (0.45) KDM4ERXFP1GAAALDH1A1HPGD
Butyric Acid SCHEMBL4158045 0.85 RXFP1 (0.39) KDM4ERXFP1GAAALDH1A1HPGD
Butyric Acid SCHEMBL4160575 0.84 KDM4E (0.44) KDM4ERXFP1GAAALDH1A1HPGD
Butyric Acid SCHEMBL4164015 0.84 KDM4E (0.44) KDM4ERXFP1GAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 KDM4E 1970/4885RXFP1 3999/4885GAA 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.